TrialNature medicine2024

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.

F D Richard Hobbs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.